[{"id":"955c5465-ea4e-4842-8504-e6f530022df5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07043270","created_at":"2025-07-05T13:59:36.534Z","updated_at":"2025-07-05T13:59:36.534Z","phase":"Phase 2","brief_title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","source_id_and_acronym":"NCT07043270","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-07-02"},{"id":"95dd2ce0-ed59-4a61-b9b8-24f3c51885f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020065","created_at":"2025-06-14T13:53:41.046Z","updated_at":"2025-06-14T13:53:41.046Z","phase":"Phase 2","brief_title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 \u003c50%","source_id_and_acronym":"NCT07020065","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-13"},{"id":"5561c46c-9fe6-437d-a39f-ed6b0feba556","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998940","created_at":"2025-06-07T14:48:14.371Z","updated_at":"2025-06-07T14:48:14.371Z","phase":"Phase 3","brief_title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","source_id_and_acronym":"NCT06998940","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 01/06/2026","start_date":" 01/06/2026","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-05-31"},{"id":"f43e758f-4bc3-4256-ae14-899721a6e9b8","acronym":"GALENT-BT","url":"https://clinicaltrials.gov/study/NCT06963060","created_at":"2025-09-07T01:31:36.203Z","updated_at":"2025-09-07T01:31:36.203Z","phase":"Phase 2","brief_title":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","source_id_and_acronym":"NCT06963060 - GALENT-BT","lead_sponsor":"Wei Gong","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 44","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-05-08"},{"id":"3d25c448-acf8-4e6b-a932-342422e06f4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06908304","created_at":"2025-09-07T01:12:54.209Z","updated_at":"2025-09-07T01:12:54.209Z","phase":"Phase 3","brief_title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","source_id_and_acronym":"NCT06908304","lead_sponsor":"Maia Biotechnology","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 07/29/2026","primary_completion_date":" 07/29/2026","study_txt":" Completion: 07/29/2027","study_completion_date":" 07/29/2027","last_update_posted":"2025-04-08"},{"id":"a4247f5e-b84a-4f2b-a095-1fca8e76f331","acronym":"","url":"https://clinicaltrials.gov/study/NCT06905509","created_at":"2025-08-02T14:06:01.421Z","updated_at":"2025-08-02T14:06:01.421Z","phase":"Phase 2","brief_title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT06905509","lead_sponsor":"University of California, Davis","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-04-01"},{"id":"0d632197-009b-4cc8-8b15-f154cec2fe79","acronym":"ACCIO","url":"https://clinicaltrials.gov/study/NCT04267848","created_at":"2021-01-18T20:44:14.334Z","updated_at":"2025-02-25T12:37:33.994Z","phase":"Phase 3","brief_title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial","source_id_and_acronym":"NCT04267848 - ACCIO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 1210","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-24"},{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"913a7f90-f43b-43fc-9a5c-45399bce2739","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907475","created_at":"2021-01-18T19:14:04.518Z","updated_at":"2025-02-25T13:39:50.577Z","phase":"Phase 2","brief_title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)","source_id_and_acronym":"NCT03907475","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD4 • IL2","pipe":"","alterations":" ","tags":["TMB • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"72d8c724-8d53-4e69-afd5-a79ba1831075","acronym":"REMAIN","url":"https://clinicaltrials.gov/study/NCT06029270","created_at":"2023-09-08T20:10:10.653Z","updated_at":"2025-02-25T13:55:33.082Z","phase":"Phase 2","brief_title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","source_id_and_acronym":"NCT06029270 - REMAIN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 04/30/2029","primary_completion_date":" 04/30/2029","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"8d3fc0b2-6af5-4276-b9b3-c9f1505975ad","acronym":"KEYNOTE-D74","url":"https://clinicaltrials.gov/study/NCT05911295","created_at":"2023-06-22T20:09:18.721Z","updated_at":"2025-02-25T13:55:18.081Z","phase":"Phase 3","brief_title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","source_id_and_acronym":"NCT05911295 - KEYNOTE-D74","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"29707765-41ef-4904-94a6-cabf9f766606","acronym":"IMpower030","url":"https://clinicaltrials.gov/study/NCT03456063","created_at":"2021-01-18T17:02:24.865Z","updated_at":"2025-02-25T14:01:22.616Z","phase":"Phase 3","brief_title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","source_id_and_acronym":"NCT03456063 - IMpower030","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" IRF1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IRF1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-19"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"a5794ed7-ec20-4c8e-af55-9e059e2c03e3","acronym":"RASolute 302","url":"https://clinicaltrials.gov/study/NCT06625320","created_at":"2025-02-25T14:19:38.953Z","updated_at":"2025-02-25T14:19:38.953Z","phase":"Phase 3","brief_title":"Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06625320 - RASolute 302","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"6012d2b0-c674-470f-8b4e-8b5f593328fd","acronym":"NEOSPACE","url":"https://clinicaltrials.gov/study/NCT03734809","created_at":"2021-01-18T18:17:38.881Z","updated_at":"2025-02-25T14:40:02.842Z","phase":"Phase 2","brief_title":"NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer","source_id_and_acronym":"NCT03734809 - NEOSPACE","lead_sponsor":"Chinese University of Hong Kong","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • gemcitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 05/03/2019","start_date":" 05/03/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-14"},{"id":"efdddd68-b037-4a5e-906c-80c7cd541d58","acronym":"DOVE","url":"https://clinicaltrials.gov/study/NCT06023862","created_at":"2023-09-05T18:12:37.255Z","updated_at":"2025-02-25T13:13:29.101Z","phase":"Phase 2","brief_title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","source_id_and_acronym":"NCT06023862 - DOVE","lead_sponsor":"Yonsei University","biomarkers":" MSI • PD-1 • WT1","pipe":"","alterations":" ","tags":["MSI • PD-1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/22/2024","start_date":" 01/22/2024","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-14"},{"id":"f3d0b4ce-a825-4e88-abe6-0a2852f91550","acronym":"SUNMO","url":"https://clinicaltrials.gov/study/NCT05171647","created_at":"2021-12-29T14:53:50.426Z","updated_at":"2025-02-25T14:41:08.199Z","phase":"Phase 3","brief_title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05171647 - SUNMO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-14"},{"id":"5bdc28e5-7ca8-447b-ae67-6e292adebde6","acronym":"TRIFOUR","url":"https://clinicaltrials.gov/study/NCT05181462","created_at":"2022-01-06T22:53:40.626Z","updated_at":"2025-02-25T15:12:31.656Z","phase":"Phase 1/2","brief_title":"Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.","source_id_and_acronym":"NCT05181462 - TRIFOUR","lead_sponsor":"Cantargia AB","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • nadunolimab (CAN04)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-13"},{"id":"6858793b-66b6-4bd1-8de9-e5db913af128","acronym":"","url":"https://clinicaltrials.gov/study/NCT03533582","created_at":"2021-01-18T17:24:25.522Z","updated_at":"2025-02-25T15:10:48.947Z","phase":"Phase 3","brief_title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","source_id_and_acronym":"NCT03533582","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCB1 • AFP","pipe":" | ","alterations":" AFP elevation","tags":["SMARCB1 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 05/24/2018","start_date":" 05/24/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"b91c94f1-41f7-4fe2-83f9-441496a86f3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919537","created_at":"2023-06-26T14:09:25.129Z","updated_at":"2025-02-25T15:13:34.765Z","phase":"Phase 1","brief_title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","source_id_and_acronym":"NCT05919537","lead_sponsor":"Hummingbird Bioscience","biomarkers":" ERBB3 • NRG1 • EGF","pipe":" | ","alterations":" NRG1 fusion","tags":["ERBB3 • NRG1 • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • albumin-bound paclitaxel • HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-13"},{"id":"6d9c9dc1-5735-46b5-bfc4-9aa69eeeef0c","acronym":"BFAST","url":"https://clinicaltrials.gov/study/NCT03178552","created_at":"2021-01-18T15:40:25.224Z","updated_at":"2025-02-25T15:17:28.532Z","phase":"Phase 2/3","brief_title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03178552 - BFAST","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • TMB","pipe":"","alterations":" ","tags":["BRAF • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • docetaxel • Alecensa (alectinib) • Cotellic (cobimetinib) • pemetrexed • divarasib (RG6330)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 08/03/2028","primary_completion_date":" 08/03/2028","study_txt":" Completion: 08/03/2028","study_completion_date":" 08/03/2028","last_update_posted":"2025-02-12"}]